Quantum Acceleration

Oncolabs.bio Partners with IBM and NVIDIA for Breakthrough AI-Quantum Discoveries

AI-Quantum Discoveries

Bengaluru, India – September 15, 2025 – Oncolabs.bio, a pioneering AI-driven biotech startup headquartered in Bengaluru, today announces a transformative collaboration with global technology leaders IBM and NVIDIA to revolutionize drug discovery for Triple Negative Breast Cancer (TNBC) — one of the most aggressive and treatment-resistant forms of breast cancer.

• Affects ~10–15% of breast cancer cases
• Higher incidence in younger women and certain ethnic groups
• No targeted therapies currently approved
• Higher recurrence and poorer prognosis compared to other subtypes

Harnessing AI, Quantum & Accelerated Computing

• Oncolabs.bio’s proprietary AI platform analyzes massive human disease datasets (genomics, transcriptomics, proteomics, clinical outcomes) to uncover subtype-specific vulnerabilities.
• IBM provides hybrid quantum-classical computing power (via IBM Quantum platforms) to tackle complex molecular optimization and explore vast chemical spaces.
• NVIDIA delivers accelerated computing with GPUs, CUDA-Q for quantum workflows, and AI tools like BioNeMo for generative modeling and high-throughput screening.

Focus: The PI3K/AKT/mTOR Pathway — Dysregulated in up to 60% of TNBC cases due to PIK3CA mutations or PTEN loss, this cascade drives tumor growth, survival, and therapy resistance.

The partners use AI for pathway deconvolution and target prediction (e.g., AKT isoforms, mTOR complexes). IBM quantum algorithms optimize designs for difficult binding sites, while NVIDIA infrastructure scales simulations to generate novel candidates with improved potency, selectivity, and reduced toxicity.

“Quantum computing unlocks ‘undruggable’ targets in pathways like PI3K/AKT/mTOR, and NVIDIA’s acceleration makes it scalable,” said Deva Reddy, Founder of Oncolabs.bio. “This partnership is set to deliver faster, more effective TNBC therapies.”

Early Momentum & Impact

Early simulations show dramatic timeline compression — from years to months — with leads progressing toward in vitro validation. This could lower the ~90% historical drug failure rate and democratize advanced therapies in high-incidence regions.

Bengaluru’s biotech ecosystem, bolstered by institutions like the Indian Institute of Science, positions India at the forefront of global quantum-AI oncology innovation.

Oncolabs.bio, IBM, and NVIDIA are pioneering the next era of precision medicine — one qubit, one GPU, and one breakthrough at a time — bringing new hope to TNBC patients worldwide.

For more information, visit Oncolabs.bio or explore resources from IBM Quantum and NVIDIA BioNeMo.

Oncolabs.bio Partners with IBM and NVIDIA for Breakthrough AI-Quantum Discoveries

Bengaluru, India – November 10, 2025 – Oncolabs.bio, a pioneering AI-driven biotech startup headquartered in Bengaluru, today announces a transformative collaboration with global technology leaders IBM and NVIDIA to revolutionize drug discovery for hematological cancers, with a focus on Acute Myeloid Leukemia (AML) — one of the most aggressive and deadly forms of blood cancer.

Key facts about AML and Hematological Cancers:

• AML represents ~1% of all cancers but 20% of childhood leukemias.
• Higher incidence in adults over 65, but rising in younger demographics.
• FLT3 mutations occur in ~30% of AML cases, driving aggressive disease.
• Limited targeted options; high relapse rates (>50% in high-risk groups).

Harnessing AI, Quantum & Accelerated Computing

• Oncolabs.bio’s proprietary AI platform analyzes massive human disease datasets (genomics, transcriptomics, proteomics, clinical outcomes) to uncover subtype-specific vulnerabilities in hematological malignancies.
• IBM provides hybrid quantum-classical computing power (via IBM Quantum platforms) to tackle complex molecular optimization and explore vast chemical spaces.
• NVIDIA delivers accelerated computing with GPUs, CUDA-Q for quantum workflows, and AI tools like BioNeMo for generative modeling and high-throughput screening.

Focus: The FLT3 Pathway — FLT3 (FMS-like tyrosine kinase 3) is a receptor tyrosine kinase mutated in up to 30% of AML cases (e.g., ITD or TKD mutations), leading to constitutive activation that promotes leukemic cell proliferation, survival, and resistance to apoptosis. This pathway drives poor prognosis and rapid disease progression.

The partners use AI for pathway deconvolution and target prediction (e.g., FLT3 kinase domain or downstream effectors). IBM quantum algorithms optimize designs for challenging binding sites, while NVIDIA infrastructure scales simulations to generate novel inhibitors with enhanced potency, selectivity, reduced off-target effects, and ability to overcome resistance mutations—potentially surpassing existing FLT3 inhibitors like gilteritinib or quizartinib.

“Quantum computing unlocks ‘undruggable’ aspects of targets like FLT3, and NVIDIA’s acceleration makes it scalable for complex hematological cancers,” said Deva Reddy, Founder of Oncolabs.bio. “This partnership is set to deliver faster, more effective therapies for AML patients facing limited options.”

Early Momentum & Impact

Early simulations demonstrate dramatic timeline compression—from years to months—with leads advancing toward in vitro validation. This could lower the ~90% historical drug failure rate, improve remission rates, and democratize advanced therapies in high-burden regions like India.

Bengaluru’s biotech ecosystem, bolstered by institutions like the Indian Institute of Science, positions India at the forefront of global quantum-AI oncology innovation for blood cancers.

Oncolabs.bio, IBM, and NVIDIA are pioneering the next era of precision medicine—one qubit, one GPU, and one breakthrough at a time—bringing new hope to patients with FLT3-driven hematological cancers worldwide.

For more information, visit Oncolabs.bio or explore resources from IBM Quantum and NVIDIA BioNeMo.

Oncolabs.bio Partners with IBM and NVIDIA for Nature-Inspired AI-Quantum Breakthroughs

Bengaluru, India – October 10, 2025 – Oncolabs.bio, a pioneering AI-driven biotech startup headquartered in Bengaluru, today announces a transformative collaboration with global technology leaders IBM and NVIDIA to revolutionize drug discovery for Colorectal Cancer (CRC) — unlocking nature's vast chemistry to deliver better, faster medicines.

Key facts about Colorectal Cancer:

• Accounts for ~10% of all cancers and cancer deaths worldwide
• Rising in younger adults; 5-year survival ~65% overall, ~12% for metastatic
• Natural compounds historically inspire ~50% of oral medicines, yet vast potential remains untapped

Harnessing AI, Quantum & Accelerated Computing – Inspired by Nature

• Oncolabs.bio’s proprietary AI platform analyzes massive human disease datasets alongside nature's evolutionary intelligence (plant-derived proteins, traditional insights) to uncover subtype-specific vulnerabilities in CRC.
• IBM provides hybrid quantum-classical computing to optimize molecular designs from complex natural scaffolds and explore vast chemical spaces.
• NVIDIA delivers accelerated computing with GPUs, CUDA-Q for quantum workflows, and AI tools like BioNeMo for generative modeling of bio-inspired candidates.

Focus: Wnt/β-Catenin Pathway – Unlocking Nature's Hidden Chemistry — This core CRC driver promotes proliferation and resistance. Drawing from natural proteins (e.g., flavonoids, alkaloids from traditional sources), the partners use AI for pathway deconvolution/target prediction (e.g., β-catenin, GSK-3β, Axin), then quantum algorithms to design optimized, nature-mimicking inhibitors with superior potency, selectivity, and reduced toxicity — translating evolutionary wisdom into precision therapies.

“By harnessing nature’s smart chemistry with quantum and accelerated computing, we unlock ‘undruggable’ targets faster than ever,” said Deva Reddy, Founder of Oncolabs.bio. “This partnership brings nature-inspired breakthroughs to CRC patients in India and beyond.”

Early Momentum & Impact

Early simulations show timeline compression from years to months, with leads advancing to in vitro validation. This could slash the ~90% drug failure rate and democratize therapies in high-burden regions.

Bengaluru’s biotech ecosystem, bolstered by the Indian Institute of Science, positions India as a leader in quantum-AI, nature-inspired oncology.

Oncolabs.bio, IBM, and NVIDIA are pioneering precision medicine — one qubit, one GPU, one nature-inspired breakthrough at a time — offering new hope for CRC worldwide.

For more information, visit Oncolabs.bio or explore resources from IBM Quantum and NVIDIA BioNeMo.